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Radiopharmaceuticals are radioactive drugs that are
used in nuclear medicine practice for diagnosis and
treatment of disease. Nuclear pharmacy practice is a
patient-oriented pharmaceutical service that pro-
motes the safe and efficacious use of radiopharma-
ceuticals and other drugs used in nuclear medicine,
and is regulated jointly by a variety of federal, state,
and local agencies. Given that the medical use of
radiopharmaceuticals is highly regulated at multiple
levels of government, it is not surprising that nuclear
pharmacy practice is conducted in a complex regula-
tory environment. The purpose of this article is to
provide a brief overview of this regulatory environ-
ment, primarily in terms of two important regulatory
agencies involved (Nuclear Regulatory Commission
and Food and Drug Administration), their primary
authority and activities, and the regulations that
must be satisfied in order to assure the safe and
efficacious use of radiopharmaceuticals.
&copy; 1989 by W.B. Saunders Company.
THE MEDICAL USE OF
RADIOPHARMACEUTICALS
~ ADIOPHARMACEUTICALS are radioac-tive prescription drug products that are
internally administered and intended for use in
the diagnosis and treatment of disease. The term
radiopharmaceutical also applies to nonradioac-
tive reagent kits and radionuclide generators
intended for use in the preparation of radioactive
drugs and radioactive biological drug products;
however, it does not include substances that
contain trace quantities of naturally occurring
radionuclides or sealed radionuclide sources.
The radiopharmaceuticals used in nuclear med-
icine are procured from commercial pharmaceu-
tical companies that specialize in the manufac-
ture and distribution of radioactive dosage forms.
The majority of these radiopharmaceuticals are
small volume parenterals, although oral solu-
tions, capsules, aerosols, and gases are also used.
Several of these radiopharmaceuticals are pro-
vided as final dosage forms ready for patient
administration; however, the majority must be
prepared (ie, compounded) just before patient
administration due to their short physical half-
life (ie, rapid radioactive decay) and in some
cases limited chemical stability. Radiopharma-
ceuticals are typically prepared by nuclear phar-
macists who practice in hospital pharmacies
and/or nuclear medicine departments or within
community-based centralized nuclear pharma-
cies. The majority of nuclear pharmacists prac-
tice in the centralized nuclear pharmacies that
are generally located in large cities. These central-
ized nuclear pharmacies provide service to the
majority of the hospitals and private nuclear
medicine clinics located within each city and
surrounding metropolitan or geographic area.
Although nuclear pharmacy services are widely
available, it is not uncommon to find that the
basic pharmacy function is served by nuclear
medicine technologists under the direct supervi-
sion of a qualified nuclear medicine physician.
This arrangement is permissible in any clinical
setting as it constitutes the practice of medicine.
However, it is important to note that the hospital
pharmacist must be aware of his or her responsi-
bility to monitor the use of all drugs within the
hospital including those used in nuclear medi-
cine.
NUCLEAR PHARMACY PRACTICE STANDARDS
Nuclear pharmacy practice standardsl have
been developed to supplement competency-based
pharmacy practice standards and to identify
those areas of responsibility that are unique to
nuclear pharmacy. The standards function as
guidelines for nuclear pharmacy practitioners
and also provide the practice-oriented foundation
upon which a competency-based certification
exam is derived. These standards may also be
useful to nuclear medicine physicians and technol-
ogists involved in the medical use of radiopharma-
ceuticals ; however, the standards are not in-
tended to govern the activities of these individuals.
In addition, it is important to realize that many
of these standards of practice are derived from
existing regulations governing the medical use of
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radioactive materials; thus, there may be a legal
requirement to comply with the described activi-
ties.
Nuclear pharmacy practice is a basic patient-
oriented pharmaceutical service that embodies
the scientific knowledge and professional judg-
ment required to improve and promote health
through assurance of the safe and efficacious use
of radioactive drugs for diagnosis and therapy.1
It is important to note that nuclear pharmacists
practice in a variety of settings; therefore, their
responsibilities may vary significantly in individ-
ual practice. The general areas of responsibility
that comprise the practice of nuclear pharmacy
include, but are not limited to, the procurement,
compounding, quality control, dispensing, and
distribution of radiopharmaceutical and pharma-
ceutical drug products used in nuclear medicine.
In addition to these services, nuclear pharmacists
It is important to note that the
hospital pharmacist must be
aware of his or her
responsibility to monitor the
use of all drugs within the
hospital including those used in
nuclear medicine.
supervise supportive personnel, act as consultants
and drug information specialists, conduct phar-
maceutical and clinical research, act as radiation
safety officers, and manage the complex regula-




The regulatory history of radiopharmaceuti-
cals is fairly complex and is marked by several
well documented milestones. The first significant
regulatory event occurred with the enactment of
the 1938 Food, Drug, and Cosmetic (FD&C)
Act, which for the first time required that the
safety of all new drugs be proved to the Food and
Drug Administration (FDA) before marketing.
Approximately 6 years later, the Public Health
Services Act of 1944 authorized the Bureau of
Biologics of the FDA to regulate radioactive
biological drug products. During the formative
years of nuclear medicine, radiopharmaceuticals
were chiefly controlled by the Atomic Energy
Commission (AEC)2 as they contained by-
product radionuclides (ie, radioactive materials
produced in nuclear reactors). The 1954 Atomic
Energy Act authorized the AEC to license the
possession, use, and transfer of by-product mate-
rial, including radiopharmaceuticals. The enact-
ment of the Kefauver-Harris Drug Amendments
of 1962 increased federal control over the meth-
ods of production and testing of drugs before
their release for sale to the public, and conse-
quently threatened the availability of radiophar-
maceuticals. This problem was solved in 1963 3
when the FDA allowed a temporary exemption
for radioactive new drugs and biologicals from
the investigational new drug (IND) regulations,
provided they were distributed in complete com-
pliance with existing AEC regulations. The pri-
mary purpose of the temporary exemption was to
allow the continued availability of radioactive
drugs, manufactured from reactor-produced radi-
onuclides, until such time that the FDA and
AEC reached agreement regarding effective reg-
ulations that would minimize unnecessary dupli-
cation of regulatory control. The temporary ex-
emption was rescinded, in part, on November 3,
1971, when the FDA actively entered the regula-
tory arena with the publication of new drug
application (NDA) requirements for radioactive
drugs.4 The new regulations identified specific
radiopharmaceuticals that were no longer ex-
empt from the new drug regulations because they
were considered to be well established in nuclear
medicine practice. Both the AEC and FDA
concluded that it was inappropriate for these
radiopharmaceuticals to be distributed under the
investigational new drug exemption when they
were intended for routine clinical use.4
During the transition period that followed,
radiopharmaceutical manufacturers were al-
lowed to distribute only those radioactive drug
products for which an NDA, biological product
license, or an IND was approved by the FDA. As
a result of these regulatory requirements, 52
radiopharmaceutical NDAs were submitted and
approved from 1971 through 1975 versus only 31 1
from 1951 through 1970.5 On July 25, 1975, the
FDA issued a final rule 6 which totally revoked
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the investigational new drug exemption and
placed radiopharmaceuticals fully under the
FDA’s authority as are all other drug products.
The penultimate regulatory milestone was
reached on January 19, 1975 following the pas-
sage of the Energy Reorganization Act of 1974.
The act abolished the AEC and created the
Nuclear Regulatory Commission (NRC) which
is now responsible for all licensing and regulatory
functions originally assigned to the AEC by the
Atomic Energy Act of 1954 (as amended).
THE CURRENT REGULATORY ENVIRONMENT
The medical use of radiopharmaceuticals is
currently regulated by a variety of federal, state,
and local agencies, which bear responsibility for
assuring the general public that radiopharmaceu-
ticals are used in a safe and efficacious manner.
Recently, Vandergrift7 used a diagram to show
the relationship between a nuclear medicine
facility and various federal and state regulatory
agencies. This diagram is useful; however, it does
not fully describe the current regulatory environ-
ment as it fails to reflect the involvement of
boards of medicine and pharmacy at the state
level. Figure 1 more clearly portrays the current
regulatory environment in which radiopharma-
ceuticals are used and reveals the regulatory
relationships that exist between the medical use
of radiopharmaceuticals and various regulatory
agencies. As indicated, the NRC or an agree-
ment state agency has primary and general
authority over the medical use of radiopharma-
ceuticals in a given locale. State boards of medi-
cine and pharmacy have only general authority
in that they license individual practitioners who,
with appropriate training and experience, may
obtain NRC or agreement state agency authori-
zation for the medical use of radiopharmaceuti-
Fig 1. The regulatory environment associated with the
medical use of radiopharmaceuticals.
cals. The FDA and Department of Transporta-
tion have a moderate degree of regulatory
authority while the Environmental Protection
Agency and Occupational Safety and Health
Administration have only limited authority.
It is important to realize that all of the
identified agencies have significant responsibili-
ties beyond those related to the regulation of the
medical use of radiopharmaceuticals. For exam-
ple, the NRC is also responsible for regulating
the industrial use of nuclear reactor by-product
materials as well as the fissionable materials used
in the production of electrical power. In a similar
fashion, the FDA maintains responsibility for the
research and development of safe and effective
drugs, biological products, and medical devices
and their marketing, distribution, and clinical
use. A detailed discussion of all regulatory agen-
cies involved in the regulation of the medical use
of radiopharmaceuticals is beyond the intended
scope of this article; therefore, the reader is
referred elsewhere for additional detail.8-9 The
remaining discussion will be limited to a brief
overview of the regulatory authority and activi-
ties of the NRC and FDA since the regulations of
these federal agencies have the greatest impact
on nuclear pharmacy practice.
REGULATORY AUTHORITY OF THE NRC AND
THE FDA
Following the revocation of the investigational
new drug exemption for radiopharmaceuticals,
the FDA began to regulate actively the safety
and efficacy of radiopharmaceuticals with re-
spect to patients. In response, the NRC withdrew
from regulating the safety and efficacy of radio-
pharmaceuticals and began to focus its regula-
tory activities on the safety of occupational
workers and the general public. In 1979, the
NRC published a policy statement to guide its
regulation of the medical use of radiophar-
maceuticals.l° In this three-part policy state-
ment, the NRC indicated that it would: (1)
continue to regulate the medical use of radioiso-
topes as necessary to provide for the radiation
safety of workers and the general public; (2)
regulate the radiation safety where justified by
the risk to patients and where voluntary stan-
dards or compliance with these standards is
inadequate; and (3) minimize intrusion into med-
ical judgments affecting patients and into other
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areas traditionally considered to be part of the
practice of medicine. It is also important to note
that the policy statement indicated that &dquo;the
NRC intends not to exercise regulatory control
in those areas (involving patients) where, upon
careful examination, it determines that there are
adequate regulations by other Federal or State
agencies or well administered standards. The
Commission recognizes that the FDA regulates
the manufacture, interstate distribution, investi-
gational and research use of drugs, including
radiopharmaceuticals, but does not have the
authority to restrict the routine use of drugs to
the procedures (specified in the product labeling)
that FDA has approved as safe and effective. The
NRC sees itself as the only Federal Agency that
is currently authorized to regulate the routine
use of radioactive drugs from the standpoint of
reducing unnecessary radiation exposure to
patients,&dquo;’o
THE NRC AND NUCLEAR PHARMACY PRACTICE
The NRC has legislative authority to license
and regulate all aspects of the possession, use,
and disposal of by-product materials in order to
protect health and minimize danger to life and
property. Thus, it also has certain regulatory
authority over radiopharmaceuticals. This author-
ity does not, however, include the regulation of
radiopharmaceuticals that contain naturally oc-
curring or accelerator-produced radionuclides as
they are regulated at the state level. The NRC
has agreed to transfer authority to control the use
of reactor-produced materials to 29 state regula-
tory agencies. Under the current regulatory
scheme, the NRC regulates reactor-produced
materials only, the nonagreement states regulate
accelerator-produced materials only, and the
agreement states regulate all radioactive materi-
als.
All NRC regulations are published in the
Federal Register and codified in Title 10, Chap-
ter 1, of the Code of Federal Regulations (CFR).
The NRC regulations pertaining to the medical
use of by-product materials are identified in
NRC Regulatory Guide 10.811 and listed in
Table 1. The regulations that most directly affect
nuclear pharmacy practice are contained in 10
CFR 35 (Human Uses of By-product Material),
10 CFR 20 (Standards for Protection Against
Radiation), and 10 CFR 71 (Packaging and
Transportation of Radioactive Materials). The
remaining regulations are equally important in
that nuclear pharmacies must operate in total
compliance with applicable sections of each part;
however, these regulations are primarily adminis-
trative in nature and do not directly impact on
routine practice activities. Therefore, the follow-
ing discussion will focus on selected sections of 10
CFR 35 in an effort to characterize the regula-
tory relationship that exists between the NRC
and nuclear pharmacy practice.
The regulations contained in 10 CFR 35 pre-
scribe requirements and provisions for the medi-
cal use of by-product material, the issuance of
specific licenses authorizing the medical use of
this material, and the protection of the public
health and safety. Given that these are federal
regulations, it is not surprising to find that they
serve as part of the foundation upon which the
nuclear pharmacy practice standards are based.
This relationship is clearly identified in the prac-
tice standards in that nuclear pharmacists have a
professional responsibility to comply with the
NRC and/or state license(s) under which the
nuclear pharmacy operates, and federal, state
and institutional rules regulating radiation and
radiopharmaceuticals. More specifically, 10 CFR
35.11 specifies that a person shall not manufac-
Table 1. United States Nuclear Regulatory Commission Rules and Regulations Pertaining to the
Medical Use of By-Product Materials
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ture, produce, acquire, receive, possess, use, or
transfer by-product material for medical use
except in accordance with a specific license
issued by the NRC or an agreement state, which
authorizes these activities. This licensure require-
ment is reflected in the procurement practice
standards which obligate nuclear pharmacists to
act with proper authority (ie, under a valid
radioactive materials license) to purchase radio-
active material.
Title 10 CFR 35.20 specifies that each licensee
shall develop and implement a written radiation
protection program that includes provisions for
keeping radiation exposure of employees, pa-
tients, visitors, and the public as low as reason-
ably achievable (ALARA). The ALARA con-
cept is embraced throughout the practice
The ALARA concept is
embraced throughout the
practice standards as nuclear
pharmacists are obligated to
work jointly with the radiation
safety officer and/or health
physicist and nuclear medicine
physician in developing
radiation protection procedures
that comply with this legal
standard.
standards as nuclear pharmacists are obligated
to work jointly with the radiation safety officer
and/or health physicist and nuclear medicine
physician in developing radiation protection pro-
cedures that comply with this legal standard.
Numerous radiation protection procedures, such
as the use of time, distance, and shielding tech-
niques, are prescribed in the practice standards,
and additionally many of these procedures are
specifically required by regulation. For example,
10 CFR 35.60 specifies that a licensee shall
require each individual who prepares (ie, com-
pounds) a radiopharmaceutical kit to use a sy-
ringe radiation shield and shall also require
individuals to use a syringe radiation shield when
administering a radiopharmaceutical by injec-
tion unless the use of the shield is contraindicated
for that patient. This regulation also requires
each syringe or syringe radiation shield that
contains a syringe with a radiopharmaceutical to
be conspicuously labeled so that the contents
may be identified; however, this requirement is
limited to providing the radiopharmaceutical
name or its abbreviation, the clinical procedure
to be performed, or the patient’s name. In this
regard it is interesting to note that nuclear
pharmacists are obligated, under both federal
and state laws and pharmacy practice standards,
to provide for each radiopharmaceutical dosage
an appropriate prescription label containing all
legally required information.&dquo; In addition to this
required information, radiopharmaceutical pre-
scription labels must include the amount of
radioactivity, the calibration and expiration time,
and a cautionary statement and symbol indicat-
ing that the dosage is radioactive in order to
further assure that the dosage is used in a safe
and efhcacious manner.
In some instances conflict may exist between
NRC regulations and the standards of nuclear
pharmacy practice. For example, 10 CFR 35.200
specifies that a licensee may use any by-product
material in a diagnostic radiopharmaceutical or
any generator or reagent kit for the preparation
and diagnostic use of a radiopharmaceutical
containing by-product material for which the
FDA has accepted a IND or approved a NDA.
The regulation also specifies that a licensee shall
elute generators and prepare reagent kits in
accordance with the manufacturer’s instructions.
This latter requirement is seldom a problem as
nuclear pharmacists most frequently adhere to
the manufacturer’s instructions. However, as
professional practitioners, nuclear pharmacists
must reserve the right to exercise professional
judgment as appropriate to the provision of
quality nuclear pharmacy services and the over-
all safety of nuclear medicine procedures. Thus,
based upon a physician’s prescription, patient
needs, and individual experience with the pre-
scribed radiopharmaceutical, nuclear pharma-
cists may modify the manufacturer’s instructions
or in some cases develop compounding proce-
dures that are not described by the manufac-
turer. As an example, nuclear pharmacists may
establish specialized procedures for preparing
pediatric doses of technetium 99mTc Albumin
Aggregated (99mTc MAA) for pulmonary perfu-
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sion studies’ as the instructions for preparing
the radiopharmaceutical for pediatric patients in
a reasonable volume of administration are not
provided in the product labeling. Obviously,
nuclear pharmacists must consider the legal
ramifications associated with this and other prac-
tice activities that may deviate from applicable
NRC regulations.
THE FDA AND NUCLEAR PHARMACY PRACTICE
The FDA is a scientific federal regulatory
agency charged with the responsibility for ensur-
ing that: ( 1 ) foods are safe, pure, and wholesome;
(2) cosmetics are safe; (3) drugs, biological
products, and medical devices are safe and effec-
tive ; (4) radiologic products and their uses do not
result in unnecessary radiation exposure; and (5)
all these products are properly and honestly
labeled.’4 Consequently, the FDA’s regulatory
activities have a significant affect on the medical
use of radiopharmaceuticals and nuclear phar-
macy practice. The regulatory relationship that
currently exists between the FDA and nuclear
pharmacy practice has been described in a de-
tailed policy statement 15 and will be considered
briefly here.
During the formative years, nuclear pharmacy
practice activities included: (1) purchasing a
commercially prepared radiopharmaceutical from
a drug manufacturer who held an approved
NDA and dispensing the drug in its original
unopened container; (2) dispensing a single pa-
tient dose from a multiple dose container of a
commercially prepared radiopharmaceutical; and
(3) diluting (including adjustments of buffers,
bacteriostatic agents, and stabilizers) and repack-
aging a commercially prepared radiopharmaceu-
tical for subsequent use or distribution. Eventu-
ally, as technology developed and practitioners
gained more training and experience, nuclear
pharmacies expanded their activities to include:
{1) eluting a NDA approved radionuclide gener-
ator and using the eluate to compound a radio-
pharmaceutical from a nonradioactive reagent
kit; (2) preparing a nonradioactive reagent kit
’ 
for subsequent use in compounding a radiophar-
maceutical ; and (3) preparing a radiopharmaceu-
tical by using a commercially prepared radionu-
clide or a radionuclide obtained from a local
nuclear reactor or cyclotron. As these compound-
ing and distribution became more prevalent, it
became evident that even though most
nuclear pharmacy activities clearly involved phar-
macy practice, others constituted manufacturing
which required the nuclear pharmacy to register
as a drug establishment under Section 510 of the
FD&C Act. Consequently, nuclear pharmacies
that are required to register are subject to the
drug listing provisions of Section 510 of the
FD&C Act and FDA’s regulations under 21
CFR 207, the current good manufacturing prac-
tice requirements of Section 501 of the FD&C
Act and FDA’s regulations under 21 CFR 210
and 211, and the factory inspection provisions of
Section 505 of the FD&C Act and FDA’s
regulations under 21 CFR 310, 312, and 314.
As nuclear pharmacy practice matured fur-
ther, a controversy developed between practitio-
ners and the FDA regarding what nuclear phar-
macy activities should be considered as the
practice of pharmacy and what activities should
be considered as manufacturing. To aid the FDA
in establishing criteria to determine what nuclear
pharmacy activities required registration, a sub-
committee of the FDA’s Radiopharmaceuticals
Advisory Committee was appointed in October
1975 to consider the existing issues. The FDA
specifically requested that the subcommittee con-
sider : (1) the types of operations engaged in by
nuclear pharmacies that should be regulated to
some degree by FDA; and (2) the relative ur-
gency for issuing new regulations or statements
of policy, if they were needed. 
’
On April 15, 1976, the subcommittee reported
to the Radiopharmaceuticals Advisory Commit-
tee. In considering which nuclear pharmacy oper-
ations should be regulated by the FDA, the
subcommittee concluded that: ( 1 ) if the radio-
pharmaceutical was prepared and dispensed un-
der a prescription, the laws and regulations
governing the practice of pharmacy and medi-
cine at the state level should apply and the
nuclear pharmacy should be considered as engag-
ing in the practice of pharmacy; and (2) the
presence of a third party in the distribution of a
prescription drug, between the location where the
product is formulated, compounded, or manufac-
tured and the point where it is administered to
patients, changes the practice to one of manufac-
turing. Examples of the latter situation include
one in which a nuclear pharmacy sells radiophar-
maceuticals to a second pharmacy for dispensing
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pursuant to a prescription, and a second in which
a nuclear pharmacy sells to other pharmacies
bulk quantities of nonradioactive reagent kits
that it has developed. In each case the first
pharmacy would be a manufacturer under the
FD&C Act and be required to register under
Section 510 of the Act.
The subcommittee also recognized that radio-
pharmaceuticals are frequently administered by
the nuclear medicine unit in a single institution.
These units may operate a nuclear pharmacy and
maintain control over any radiopharmaceutical
manufactured or compounded within the phar-
macy until it is dispensed for patient administra-
tion. Because of the high level of control exer-
cised over the drugs in this setting, the
subcommittee concluded that there was no need
If the radiopharmaceutical was
prepared and dispensed under a
prescription, the laws and
regulations governing the
practice of pharmacy and
medicine at the state level
should apply and the nuclear
pharmacy should be considered
as engaging in the practice of
pharmacy
for registration. In addition, the subcommittee
recommended that: ( 1 ) substantive changes in
FDA regulations, as they pertain to true nuclear
pharmacies, were not needed; (2) individual state
boards of pharmacy rather than the FDA should
regulate nuclear pharmacies in the same manner
as they regulate traditional pharmacies that do
not compound or dispense radiopharmaceuticals;
and (3) the FDA should issue a policy statement
to clarify the issue of nuclear pharmacy manufac-
turing v traditional pharmacy compounding.
In response to the subcommittee’s recommen-
dations, the FDA responded with a policy
statementls to guide its regulation of the activi-
ties associated with nuclear pharmacy practice.
In this policy statement, the FDA noted that
Section 510 (g){1) of the FD&C Act [21 USC
360{g)(1)~ states that &dquo;pharmacies which main-
tain establishments in conformance with any
applicable local laws regulating the practice of
pharmacy and medicine are exempt from the
drug registration provisions of the Act. For the
exemption to apply they must be regularly en-
gaged in dispensing prescription drugs or devices,
upon prescriptions of practitioners licensed to
administer such drugs or devices to patients
under the care of such practitioners in the course
of their professional practice, and they must not
manufacture, prepare, propagate, compound, or
process drugs or devices for sale other than in the
regular course of their business of dispensing or
selling drugs or devices at retails
The FDA, however, does not believe that this
pharmacy exemption applies to all nuclear phar-
macies, because many states do not appear to
have laws that apply specifically to the practice
of nuclear pharmacy. Also, many states may not
have mechanisms specifically designed for certi-
fying nuclear pharmacists, and many nuclear
pharmacies require specifically trained personnel
whose activities resemble those of drug manufac-
turers more than those of traditional pharmacy
practice. Consequently, the FDA’s regulation of
nuclear pharmacies will be based on reasonable
application of the provisions of Section 510
{g) ( 1 ) of the FD&C Act to nuclear pharmacies
and it will treat these nuclear pharmacies as
other pharmacies have been traditionally treated
under this section. Therefore, a nuclear phar-
macy whose activities are consistent with Section
510 (g}( 1 ) of the FD &C Act will be exempt from
registering as a drug establishment and from
complying with other requirements under the
section. Conversely, a nuclear pharmacy whose
activities fall outside the provisions of Section
510 (g)(1) of the FD&C Act will be subject to
the registration provisions and to those require-
ments that are concomitant to registration. The
FDA has provided several specific examples of
cases when a nuclear pharmacy must register as
a drug establishment. 15
SUMMARY
In conclusion, all pharmacists should have a
basic understanding of the regulations governing
the medical use of radiopharmaceuticals and the
practice of nuclear pharmacy. Federal regula-
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tions promulgated by the NRC and FDA are
most important; however, state and local regula-
tions must also be given due consideration. NRC
regulations focus primarily on providing for the
radiation safety of workers and the general
public while FDA regulations focus on the safety
and efficacy of radiopharmaceuticals with re-
spect to patients. Nuclear pharmacists bear re-
sponsibility for assuring that these regulations
are satisfied and for providing the clinical phar-
macy services that are required to assure the safe
and efhcacious use of radiopharmaceuticals.
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